Key facts
- This page summarizes Sally Bridget Lawlor's Form 3 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Sep 2025, 16:31.
Sally Bridget Lawlor - 18 Aug 2025 Form 3 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- QNRX
- Reported as of
- 18 Aug 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Sep 2025, 16:31:14 UTC
- Next SEC filing
- 03 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sally Bridget Lawlor
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sally Bridget Lawlor filed Form 3 for Quoin Pharmaceuticals, Ltd. (QNRX) on 08 Sep 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002084407
Primary reporting owner
Lawlor Sally Bridget
- Relationship
- CHIEF FINANCIAL OFFICER
- Address
- C/O QUOIN PHARMACEUTICALS LTD., 42127 PLEASANT FREST COURT, ASHBURN
- Signature
- /s/ Sally Bridget Lawlor
- Signature date
- 08 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QNRX
holding
ADS
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 440
- Date
- 18 Aug 2025
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The number of securities are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
SEC remarks
Exhibit List - Exhibit 24.1: Power of Attorney